Preprint Article Version 1 This version is not peer-reviewed

Coxsackievirus A6 UK Genetic and Clinical Epidemiology Pre- and Post-SARS-CoV-2 Pandemic

Alice Joyce
,
Jack D. Hill
,
Theocharis Tsoleridis
,
Stuart Astbury
,
Louise Berry
,
Hannah C. Howson-Wells
,
Nancy Allen
,
Ben Canning
,
Carl B. Jones
,
Gemma Clark
,
William L. Irving
,
Alexander W. Tarr
,
C Patrick McClure
*
Version 1 : Received: 30 October 2024 / Approved: 31 October 2024 / Online: 31 October 2024 (07:09:06 CET)

How to cite: Joyce, A.; Hill, J. D.; Tsoleridis, T.; Astbury, S.; Berry, L.; Howson-Wells, H. C.; Allen, N.; Canning, B.; Jones, C. B.; Clark, G.; Irving, W. L.; Tarr, A. W.; McClure, C. P. Coxsackievirus A6 UK Genetic and Clinical Epidemiology Pre- and Post-SARS-CoV-2 Pandemic. Preprints 2024, 2024102518. https://doi.org/10.20944/preprints202410.2518.v1 Joyce, A.; Hill, J. D.; Tsoleridis, T.; Astbury, S.; Berry, L.; Howson-Wells, H. C.; Allen, N.; Canning, B.; Jones, C. B.; Clark, G.; Irving, W. L.; Tarr, A. W.; McClure, C. P. Coxsackievirus A6 UK Genetic and Clinical Epidemiology Pre- and Post-SARS-CoV-2 Pandemic. Preprints 2024, 2024102518. https://doi.org/10.20944/preprints202410.2518.v1

Abstract

Coxsackievirus A6 (CVA6) has become increasingly clinically relevant as a cause of Hand, Foot and Mouth Disease (HFMD) globally since 2008. However, most laboratories do not routinely determine the enteroviral type of positive samples. The non-pharmaceutical measures introduced to curb transmission during the SARS-CoV-2 pandemic may also have been perturbed CVA6 epidemiology. We thus aimed to determine the prevalence, clinical presentation and genetic relationship of CVA6 across three complete epidemic seasons: one pre- and two post-SARS-CoV-2-emergence in our regional healthcare setting. Surplus diagnostic nucleic acid from diagnosed enteroviral positives diagnosed between September to December 2018 and May 2021 to April 2023 was subject to VP1 gene sequencing to determine CVA6 cases and interrogate their phylogenetic relationship. Confirmed CVA6 cases were also retrospectively clinically audited. CVA6 infections were identified in 33 and 69 individuals pre- and post-pandemic respectively, with cases peaking in November of 2018 and 2022, but in October of 2021. HFMD was the primary diagnosis in 85.5% of post-pandemic cases, but only 69.7% pre-pandemic, where respiratory and neurological symptoms (45.5% and 12.1% respectively) were significantly elevated. Complete VP1 sequence was retrieved for 94% of CVA6 cases, revealing study infections were genetically diverse and suggestive of multiple local and international transmission chains. CVA6 presented a significant clinical burden in our regional UK hospital setting both pre- and post-pandemic and was subject to dynamic clinical and genetic epidemiology.

Keywords

Coxsackievirus A6; Enterovirus; CVA6; genetic epidemiology; Hand foot and mouth disease; HFMD

Subject

Biology and Life Sciences, Virology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.